Table 3.
Demographics and CINV characteristics of patients
| Patient demographics | Number of patients in all regimens (%)a, n = 710 | Number of patients in HEC regimens (%)a, n = 139 | Number of patients in AC-based regimens (%)a, n = 361 | Number of patients in XELOX regimens (%)a, n = 210 |
|---|---|---|---|---|
| Age (years) | ||||
| < 30 | 8 (1) | 4 (3) | 2 (1) | 2 (1) |
| 30~39 | 61 (9) | 19 (14) | 41 (11) | 1 (1) |
| 40~49 | 195 (28) | 46 (33) | 130 (36) | 19 (9) |
| 50~59 | 266 (38) | 46 (33) | 138 (38) | 82 (39) |
| ≥ 60 | 180 (25) | 24 (17) | 50 (14) | 106 (51) |
| Race | ||||
| Chinese | 593 (84) | 114 (82) | 293 (81) | 186 (89) |
| Malay | 72 (10) | 15 (11) | 43 (12) | 14 (7) |
| Indian | 23 (3) | 3 (2) | 14 (4) | 6 (3) |
| Others | 22 (3) | 7 (5) | 11 (3) | 4 (2) |
| Gender | ||||
| Male | 233 (33) | 110 (79) | 1 (0.3) | 122 (58) |
| Female | 477 (67) | 29 (21) | 360 (99.7) | 88 (42) |
| Marital status | ||||
| Single | 94 (13) | 17 (12) | 56 (16) | 21 (10) |
| Married | 571 (80) | 121 (87) | 278 (77) | 172 (82) |
| Divorced | 13 (2) | 0 (0) | 7 (2) | 6 (3) |
| Widowed | 19 (3) | 1 (1) | 7 (2) | 11 (5) |
| Highest education level | ||||
| No education | 34 (5) | 0 (0) | 19 (5) | 15 (7) |
| Primary | 185 (26) | 30 (22) | 91 (25) | 64 (31) |
| Secondary | 295 (42) | 60 (43) | 151 (42) | 84 (40) |
| Pre-university | 118 (17) | 26 (19) | 61 (17) | 31 (15) |
| Graduate | 56 (8) | 16 (12) | 30 (8) | 10 (5) |
| Postgraduate | 22 (3) | 7 (5) | 9 (3) | 6 (3) |
| CINV characteristics | Number of patients in all regimens (%)b | Number of patients in HEC regimens (%)b | Number of patients in AC-based regimens (%)b | Number of patients in XELOX regimens (%)b |
| Chemotherapy-induced nausea | ||||
| Acute | 387 (55) | 75 (54) | 240 (67) | 72 (34) |
| Delayed | 472 (67) | 90 (65) | 278 (77) | 104 (50) |
| Chemotherapy-induced vomiting | ||||
| Acute | 103 (15) | 16 (12) | 77 (21) | 10 (5) |
| Delayed | 156 (22) | 35 (25) | 89 (25) | 32 (15) |
| Complete response (CR) | ||||
| Acute | 537 (76) | 110 (79) | 243 (67) | 184 (88) |
| Delayed | 450 (63) | 77 (55) | 213 (59) | 160 (76) |
| Overall | 409 (58) | 70 (50) | 182 (50) | 157 (75) |
| Complete protection (CP) | ||||
| Acute | 428 (60) | 89 (64) | 173 (48) | 166 (79) |
| Delayed | 325 (46) | 58 (42) | 129 (36) | 138 (66) |
| Overall | 297 (42) | 51 (37) | 113 (31) | 133 (63) |
| Complete control (CC) | ||||
| Acute | 308 (43) | 62 (45) | 112 (31) | 134 (64) |
| Delayed | 219 (31) | 43 (31) | 75 (21) | 101 (48) |
| Overall | 194 (27) | 35 (25) | 62 (17) | 97 (46) |
aPercentages may not add to 100% due to missing data and rounding of figures.
bPercentages may be over 100% due to patients suffering from multiple effects.